Delta Capital Management LLC Acquires New Position in Pfizer Inc. (NYSE:PFE)
Delta Capital Management LLC acquired a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 15,958 shares of the biopharmaceutical company’s stock, valued at approximately $625,000.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Eagle Capital Management LLC raised its position in shares of Pfizer by 1.3% during the 2nd quarter. Eagle Capital Management LLC now owns 84,677 shares of the biopharmaceutical company’s stock worth $3,668,000 after purchasing an additional 1,125 shares during the last quarter. Kanawha Capital Management LLC lifted its stake in Pfizer by 3.0% in the 2nd quarter. Kanawha Capital Management LLC now owns 188,839 shares of the biopharmaceutical company’s stock valued at $8,180,000 after buying an additional 5,475 shares in the last quarter. Lido Advisors LLC grew its holdings in Pfizer by 14.1% during the 2nd quarter. Lido Advisors LLC now owns 69,926 shares of the biopharmaceutical company’s stock valued at $3,029,000 after buying an additional 8,645 shares during the last quarter. National Pension Service grew its holdings in Pfizer by 5.5% during the 2nd quarter. National Pension Service now owns 5,847,107 shares of the biopharmaceutical company’s stock valued at $253,297,000 after buying an additional 303,994 shares during the last quarter. Finally, Johnson Investment Counsel Inc. grew its holdings in Pfizer by 0.5% during the 2nd quarter. Johnson Investment Counsel Inc. now owns 160,772 shares of the biopharmaceutical company’s stock valued at $6,964,000 after buying an additional 773 shares during the last quarter. Hedge funds and other institutional investors own 70.21% of the company’s stock.
A number of research firms have recently weighed in on PFE. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price target for the company in a report on Tuesday, October 1st. Credit Suisse Group restated a “hold” rating and issued a $41.30 price objective on shares of Pfizer in a research report on Wednesday, November 6th. Royal Bank of Canada began coverage on Pfizer in a research note on Monday, January 6th. They set an “outperform” rating and a $46.00 price objective on the stock. Bank of America assumed coverage on Pfizer in a research report on Wednesday, October 16th. They set a “neutral” rating and a $37.00 price objective for the company. Finally, JPMorgan Chase & Co. reissued a “neutral” rating on shares of Pfizer in a research note on Tuesday, October 29th. Nine investment analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $43.41.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.13. Pfizer had a return on equity of 28.10% and a net margin of 30.57%. The company had revenue of $12.68 billion for the quarter, compared to analyst estimates of $12.37 billion. During the same quarter in the prior year, the company posted $0.78 EPS. The business’s revenue for the quarter was down 4.6% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.97 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 31st will be paid a $0.38 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.36. This represents a $1.52 annualized dividend and a yield of 3.80%. The ex-dividend date is Thursday, January 30th. Pfizer’s dividend payout ratio is presently 48.00%.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: What does the Producer Price Index (PPI) tell investors?
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.